Healthcare / BiotechnologyNYSE American
$0.60
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 54.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
1/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$3M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-118.9%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-9.8M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | — | — | — | $37653.00 | $131521.00 | $86987.00 | — | — | — | $0.00 | $0.00 | $0.00 | $939926.00 | $1.0M | $1.3M | $1.4M | $1.3M |
| Net Income | $-9.8M | $-9.8M | $-10.6M | $-20.7M | $-14.3M | $-15.7M | $-26.4M | $-15.6M | $-9.9M | $-6.7M | $-7.0M | $-11.7M | $-5.8M | $-16.1M | $-13.1M | $-7.7M | $-7.8M |
| EBITDA | — | — | — | $-20.9M | $-14.4M | $-15.7M | $-26.6M | $-15.8M | $-10.0M | $-6.7M | $-8.5M | $-11.7M | $-5.8M | $-16.1M | $-12.4M | $-7.3M | $-7.9M |
| EPS | -4.56 | -4.56 | -47.88 | -9.18 | -7.11 | -8.09 | -0.47 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | 60.7% | 66.7% | 34.0% | — | — |
| Operating Margin | — | — | — | -55519.9% | -10964.6% | -18130.3% | — | — | — | — | — | — | -618.8% | -1570.4% | -933.5% | -508.6% | -603.8% |
| Net Margin | — | — | — | -54858.1% | -10864.0% | -18062.0% | — | — | — | — | — | — | -616.0% | -1556.7% | -982.9% | -531.6% | -596.3% |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | — | — | — | — | $-15.4M | $-13.5M | — | $-13.0M | $-9.2M | — | $-7.1M | $-5.3M | — | — | $-5.2M | — | $-6.5M |
| Returns | |||||||||||||||||
| ROE | -118.9% | -118.9% | 4987.6% | -652.0% | -109.8% | -59.3% | -156.9% | -90.3% | -47.5% | -106.6% | -236.5% | -247.5% | -56.0% | -101.5% | -141.8% | 93.9% | 410.9% |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | — | — | — | -71.4% | 51.2% | — | — | — | — | — | — | -100.0% | -8.9% | -22.5% | -7.8% | 10.4% | — |
| EPS Growth | 90.5% | 90.5% | -421.6% | -29.1% | 12.1% | -1621.3% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.